International Journal of Pharmacy and Industrial Research (IJPIR)

IJPIR |Vol.15 | Issue 4 | Oct - Dec -2025
www.ijpir.com
DOI : https://doi.org/10.61096/ijpir.v15.iss4.2025.600-607

ISSN: 2231-3656
Print: 2231-3648

Research

Orally Disintegrating Tablets: Formulation Science, Mechanistic Insights, and Emerging Innovations in Patient-Centric Drug Delivery

Dr.V. Jenila Jose Jancy*[1], M. Kowsalya[2]

Department of Pharmacology, S.A.Raja Pharmacy College, Tirunelveli, Tamilnadu, India.

*Author for Correspondence: Dr.V.Jenila Jose Jancy, M.Pharm., Ph.D
Email: jenilajk3@gmail.com

Published on: 15 Oct 2025

Published by:
Futuristic Publications

Abstract

Orally disintegrating tablets (ODTs) have redefined oral drug delivery by merging the benefits of conventional solid dosage forms with the convenience and compliance advantages of liquid formulations. Designed to disintegrate rapidly on the tongue without the need for water, ODTs ensure rapid drug release, improved bioavailability, and enhanced patient adherence, particularly among pediatric, geriatric, and dysphagic populations. Over the past two decades, extensive research has focused on optimizing the formulation parameters of ODTs superdisintegrants, diluents, binders, and taste-masking agents to achieve ideal performance characteristics including rapid disintegration, pleasant mouthfeel, and adequate mechanical integrity. Technological advances, such as lyophilization, sublimation, spray drying, molding, and 3D printing, have further expanded the design possibilities of ODTs. Moreover, the integration of nanocrystals, mucoadhesive agents, and machine learning–based formulation prediction has elevated the scientific understanding of ODT performance. This review provides a detailed examination of the principles governing ODT formulation, physicochemical mechanisms of disintegration, advances in manufacturing technologies, evaluation standards, and regulatory frameworks. The article also explores the emerging frontier of 3D-printed and AI-optimized ODTs, offering insights into their clinical relevance, sustainability, and potential to transform patient-centric drug delivery systems in the coming decades.

Keywords: Orally disintegrating tablets, superdisintegrants, lyophilization, taste masking, patient compliance, disintegration mechanism.

1.0 INTRODUCTION

Orally disintegrating tablets (ODTs), also referred to as fast-dissolving or mouth-dissolving tablets, represent one of the most significant advances in oral drug delivery in the last three decades. The concept emerged in the late 1980s as a response to the clinical need for patient-friendly dosage forms that could eliminate the requirement for swallowing or water intake [1]. According to the United States Food and Drug Administration (FDA), an ODT is defined as a solid dosage form containing medicinal substances that disintegrate rapidly, usually within 30 seconds, when placed upon the tongue [2]. The design goal of ODTs is to enable rapid breakdown into smaller granules or particles that can either dissolve or be swallowed easily, facilitating pre-gastric absorption and avoiding hepatic first-pass metabolism [3].

The adoption of ODTs in therapeutic practice has grown exponentially due to their unique combination of convenience, portability, and efficacy. They are particularly valuable for pediatric and geriatric patients, psychiatric populations, and individuals suffering from dysphagia or motion sickness. The ability to administer medication without water also makes ODTs suitable for emergency situations, travel, and remote healthcare delivery [4]. Over time, their formulation has evolved from simple sugar-based systems to highly engineered matrices incorporating advanced disintegrants, co-processed excipients, and innovative fabrication methods such as freeze-drying and 3D printing [5].

Modern ODT research integrates pharmaceutical technology, material science, and sensory evaluation to achieve optimal patient experience and pharmacokinetic outcomes. The present review provides a comprehensive exploration of ODT development, encompassing formulation science, mechanistic insights, evaluation parameters, technological advancements, clinical utility, regulatory guidelines, and future perspectives in patient-centric therapeutics.

2.0 Historical Development and Evolution of Orally Disintegrating Tablets

The concept of fast-dissolving oral dosage forms originated from the need to provide rapid therapeutic action in populations unable to swallow conventional tablets or capsules. Early developments in the 1970s and 1980s focused on chewable and effervescent tablets; however, these systems required water and lacked true disintegration capability within the oral cavity [6]. The breakthrough occurred with the introduction of lyophilized systems, such as Zydis®, which combined fast disintegration with excellent taste and mechanical integrity through freeze-drying a gelatin-based matrix [7].

The early 1990s witnessed the proliferation of patented ODT technologies including Orasolv® and Durasolv®, which relied on effervescent agents and direct compression, respectively, to enhance disintegration speed [8]. The introduction of co-processed excipients and sugar alcohols such as mannitol, xylitol, and sorbitol further improved palatability and structural stability [9]. By the 2000s, ODTs had transitioned from niche products for specific patient populations to mainstream pharmaceutical formulations across multiple therapeutic areas, including central nervous system (CNS), cardiovascular, and gastrointestinal disorders [10].

Recent developments in the 2010s and 2020s have witnessed integration with digital manufacturing platforms, leading to the first FDA-approved 3D-printed ODT, Spritam® (levetiracetam) [11]. This innovation opened new possibilities for dose personalization and rapid prototyping, while the combination of machine learning and computational modeling has begun predicting disintegration kinetics and mechanical performance. The continuous evolution of ODTs thus reflects an intersection between pharmaceutical engineering, patient-centered design, and precision therapeutics [12].

3.0 Advantages and Limitations of Orally Disintegrating Tablets

The clinical and pharmaceutical advantages of ODTs are substantial and contribute significantly to patient compliance, therapeutic efficiency, and product differentiation. Foremost among these is the ease of administration without the need for water, which greatly benefits populations such as children, elderly individuals, and patients with neurological or psychiatric disorders who experience difficulty swallowing [13]. The rapid disintegration and dissolution of ODTs enable faster onset of action compared to conventional tablets, especially in conditions requiring immediate relief, such as migraine, nausea, and allergic reactions [14].

Moreover, drugs absorbed via the oral mucosa can partially bypass hepatic first-pass metabolism, thereby improving systemic bioavailability for certain molecules such as selegiline, apomorphine, and nitroglycerin [15]. The palatable and portable nature of ODTs enhances patient adherence in chronic therapy regimens, while their design allows for discreet administration, a feature appreciated in social and occupational contexts. From an industrial standpoint, ODTs extend product life cycles, offer market exclusivity through technological differentiation, and present opportunities for line extension without changing the active ingredient [16].

However, these advantages are counterbalanced by technical and stability challenges. ODTs are inherently hygroscopic, making them sensitive to humidity and necessitating specialized moisture-barrier packaging such as aluminum–aluminum blisters or desiccant-containing strips [17]. Achieving sufficient mechanical strength while maintaining rapid disintegration poses a significant formulation dilemma, as excessive

compression can retard saliva penetration. Furthermore, the direct exposure of APIs to taste receptors requires meticulous taste masking through coating, complexation, or the incorporation of flavoring and sweetening agents [18].

Other notable limitations include restricted drug loading (typically less than 500 mg), incompatibility of certain bitter or highly hygroscopic drugs, and the need for specialized equipment in technologies like lyophilization. Despite these challenges, continuous innovation in excipient engineering and process optimization has progressively mitigated these limitations, sustaining ODTs as a dynamic area of pharmaceutical research [19].

4.0 Fundamental Principles of ODT Formulation

The formulation of an ODT requires careful orchestration of physical and chemical parameters to achieve an optimal balance between disintegration speed, structural integrity, and sensory acceptability. The selection of excipients plays a crucial role, as their synergistic interactions determine the overall performance of the final dosage form.

The essential components of an ODT formulation include the active pharmaceutical ingredient (API), diluents, super disintegrants, binders, lubricants, sweeteners, and flavoring agents [20]. Diluents such as mannitol, lactose, and microcrystalline cellulose provide bulk and enhance mouthfeel, while binders like povidone and starch paste ensure cohesion. The inclusion of super disintegrants crospovidone, croscarmellose sodium, or sodium starch glycolate facilitates rapid tablet breakup upon saliva contact through mechanisms of swelling and capillary action [21].

The ideal ODT formulation must also accommodate taste-masking strategies to ensure patient acceptability. For bitter APIs, ion-exchange resins such as Indion 204, complexation with β-cyclodextrin, or polymeric coatings (e.g., Eudragit E100, HPMC) are commonly employed [22]. These approaches provide a delayed release of the drug, ensuring that unpleasant taste components are not perceived during the brief oral residence time. Moisture-protective excipients and film coatings enhance stability under tropical conditions, while lubricant and glidant optimization ensures uniform flow during compression [23].

The formulation process must further account for physicochemical properties of the drug such as solubility, hygroscopicity, and particle size, which directly affect disintegration and dissolution kinetics. Newer trends emphasize the integration of multifunctional co-processed excipients such as F-Melt®, Ludiflash®, and Pharmaburst®, which combine diluent, binder, and superdisintegrant functionalities into a single composite system, simplifying formulation and ensuring consistency [24].

5.0 Mechanisms of Tablet Disintegration in the Oral Cavity

The rapid disintegration of ODTs in the oral cavity is driven by a combination of physicochemical mechanisms that act synergistically to promote tablet breakup. The primary mechanisms include swelling, capillary action (wicking), and deformation recovery, each influenced by the structural and surface characteristics of the formulation [25].

In the swelling mechanism, superdisintegrant particles absorb saliva, expand in volume, and generate internal stress that breaks the tablet matrix apart. Sodium starch glycolate and croscarmellose sodium are classical examples of swellable disintegrants, capable of absorbing several times their weight in water within seconds [26]. The capillary or wicking mechanism relies on hydrophilic particles drawing moisture through the porous tablet structure, thereby weakening interparticulate bonds and promoting disintegration. Crospovidone operates predominantly through this mechanism, as its non-swellable, cross-linked polymeric structure facilitates rapid liquid uptake [27].

Deformation recovery refers to the elastic rebound of particles compressed during tablet formation. Upon contact with moisture, these particles regain their original shape, producing internal stresses that aid tablet fragmentation. Additionally, the release of entrapped gases from effervescent agents such as citric acid–sodium bicarbonate combinations accelerates disintegration through mechanical disruption [28].

The presence of hydrophilic fillers and soluble sugars further enhances saliva penetration, while the incorporation of porous structures through techniques such as sublimation or lyophilization enhances capillarity and fluid diffusion. The net effect of these mechanisms results in a disintegration time typically ranging between 5 and 30 seconds, depending on formulation design and environmental conditions [29].

6.0 Manufacturing Technologies for Orally Disintegrating Tablets

The development of ODTs has been closely associated with technological innovation in manufacturing processes. Modern fabrication techniques seek to balance rapid disintegration with adequate mechanical integrity, aesthetic appeal, and manufacturability. Several major categories of ODT technologies are recognized, each characterized by distinct process parameters and product attributes.

6.1 Direct Compression Technology

Direct compression is the most commonly used and economically viable approach for industrial-scale ODT production. It employs a blend of directly compressible excipients, including microcrystalline cellulose, mannitol, and co-processed disintegrant systems [30]. The method's simplicity, low thermal stress, and compatibility with moisture-sensitive drugs make it ideal for most formulations. Advanced excipient systems like Ludiflash® and Pharmaburst® enhance flowability and compressibility while delivering disintegration within 15–20 seconds. The challenge, however, lies in ensuring sufficient mechanical strength at lower compression forces, as overcompression may prolong disintegration [31].

6.2 Lyophilization (Freeze-Drying)

Lyophilized ODTs exhibit extremely fast disintegration often below 10 seconds due to their high porosity. The process involves preparing an aqueous dispersion of the drug with film-forming agents (e.g., gelatin, mannitol, sorbitol), freezing the mixture, and subliming the solvent under vacuum [32]. The resultant tablets are lightweight and fragile, necessitating specialized peel-off packaging. Commercial examples include Zydis® (Catalent Pharma) and Lyoc®. The method is especially suitable for low-dose, potent APIs but remains cost-intensive and moisture sensitive [33].

6.3 Molding and Sublimation Techniques

Molding involves the preparation of a semi-solid mass by moistening or heating excipients and then molding into tablets under low pressure. Heat-molded ODTs show improved dissolution but tend to have lower hardness. In contrast, sublimation employs volatile substances like camphor or ammonium bicarbonate, which are removed post-compression to create porous matrices that facilitate saliva penetration [34].

6.4 Spray Drying and Freeze Granulation

Spray drying is used to generate highly porous, spherical particles with good compressibility and rapid dissolution. Mannitol-based spray-dried powders are frequently utilized for ODT manufacturing, providing smooth texture and quick disintegration [35]. Freeze granulation, though less common, ensures uniform particle morphology and is suitable for heat-sensitive drugs.

6.5 Three-Dimensional (3D) Printing

The emergence of 3D printing has introduced a new paradigm in ODT manufacturing, allowing personalized dose fabrication and structural optimization. The FDA-approved Spritam® employs ZipDose® technology, which deposits aqueous layers containing drug and excipient blends, producing a highly porous matrix that dissolves in under 5 seconds [36]. 3D printing enables unprecedented control over porosity, geometry, and dose, marking a transformative step in digital pharmaceutics. Ongoing research focuses on biodegradable polymers, bioprinting integration, and AI-guided design optimization [37].

7.0 Evaluation and Quality Control of Orally Disintegrating Tablets

The quality evaluation of orally disintegrating tablets (ODTs) is critical to ensure their efficacy, safety, and patient acceptability. Because ODTs must balance rapid disintegration with mechanical robustness, they are subjected to both conventional tablet evaluation tests and specialized assessments tailored to their unique properties.

The fundamental physical parameters include hardness, friability, weight variation, thickness, and uniformity of content. ODT hardness typically ranges from 30–50 N, lower than conventional tablets, to allow rapid breakup while maintaining integrity during handling [38]. Friability should remain below 1%, ensuring adequate resistance to chipping and abrasion during packaging and transportation [39].

The hallmark parameter disintegration time is measured using a modified United States Pharmacopeia (USP) apparatus with simulated saliva or distilled water maintained at 37 °C. According to FDA guidance, an ODT should disintegrate within 30 seconds, although lyophilized systems such as Zydis® achieve disintegration in less than 10 seconds [40]. The wetting time test, which measures the duration required for water to penetrate the tablet matrix, serves as an indirect indicator of disintegration efficiency.

In vitro dissolution studies are performed using USP Apparatus II (paddle method), ensuring that at least 85% of the drug is released within 15 minutes [41]. The dissolution profile must correlate with in vivo disintegration behavior to predict bioavailability accurately. Texture analyzers and penetrometers are increasingly employed to measure tablet mechanical properties, while electronic tongues are used to assess **taste masking** and mouthfeel performance objectively [42].

Advanced analytical tools have enhanced the precision of ODT evaluation. Near-infrared (NIR) spectroscopy, Raman mapping, and X-ray microtomography enable non-destructive quality control by analyzing uniformity, porosity, and drug distribution in compressed tablets [43]. Stability studies under International Council for Harmonisation (ICH) conditions (40 °C ± 2 °C/75 % ± 5 % RH) are mandatory to evaluate moisture sensitivity

and chemical stability [44]. These comprehensive assessments ensure consistent product performance across manufacturing batches and climatic zones, establishing confidence in ODT quality and functionality.

8.0 Sensory Evaluation and Taste-Masking Strategies

Patient acceptance of ODTs relies heavily on sensory properties, particularly taste, mouthfeel, and aftertaste. As the drug disintegrates in the oral cavity, APIs come into direct contact with taste buds, making taste masking a crucial step in formulation development. Several approaches physical, chemical, and physiological are utilized to mitigate unpleasant flavors and ensure a pleasant mouthfeel [45].

Coating-based masking employs hydrophobic or pH-dependent polymers such as Eudragit® E100, cellulose acetate phthalate, or polyvinyl acetate to prevent direct drug–tongue contact. These coatings dissolve only upon reaching gastric pH, thereby releasing the API post-swallowing [46]. Ion-exchange resins (e.g., Indion® 204, Tulsion® 335) entrap bitter drug molecules, releasing them through ionic exchange in the gastrointestinal tract. Complexation with cyclodextrins forms inclusion complexes that encapsulate hydrophobic drug regions, thereby suppressing bitterness [47].

Microencapsulation and nanocoating have emerged as modern techniques that enhance the uniformity of taste masking while preserving disintegration speed. Spray-drying and fluid-bed coating technologies enable precise control over coating thickness and particle morphology [48]. Additionally, flavoring agents such as menthol, peppermint, orange, and strawberry combined with sweeteners like sucralose, aspartame, and acesulfame potassium improve palatability.

The electronic tongue (E-tongue), based on potentiometric sensor arrays and chemometric modeling, has become an invaluable tool for objective taste evaluation, reducing dependency on human sensory panels and providing reproducible data [49]. Research from the past decade highlights machine learning algorithms integrated with E-tongue data for quantitative correlation between formulation variables and bitterness intensity, expediting the optimization of taste-masking systems [50].

9.0 Packaging and Stability Considerations

Due to their porous nature and hydrophilic excipients, ODTs are highly sensitive to moisture and mechanical stress. Consequently, packaging design plays a pivotal role in ensuring long-term stability and product integrity. The choice of packaging material depends on the formulation's moisture sensitivity, disintegration kinetics, and shelf-life requirements.

Blister packs are the most widely used ODT packaging format. Aluminum–aluminum (Al–Al) blisters provide the highest moisture barrier, followed by aluminum–PVC laminates. Lyophilized ODTs typically require peelable aluminum foil blisters with individual cavities to prevent mechanical deformation [51]. Desiccant sachets and humidity indicators are sometimes integrated within secondary cartons for additional protection.

Strip packaging using laminated aluminum films offers a cost-effective alternative for direct compression ODTs. However, these must comply with tight sealing parameters to prevent moisture ingress [52]. For tropical markets, high-barrier multilayer laminates combining polyamide and polyethylene are recommended.

Stability testing under accelerated conditions, as outlined in ICH Q1A(R2), ensures formulation robustness against degradation. Parameters such as hardness, disintegration, drug assay, and moisture content are monitored periodically. Studies have demonstrated that incorporation of moisture-protective excipients such as sorbitol or mannitol improves stability and maintains disintegration efficiency after prolonged storage [53].

The development of smart packaging systems equipped with embedded humidity sensors and desiccant films has recently gained attention. These technologies can dynamically adjust internal humidity levels or provide real-time stability monitoring, aligning with the principles of Industry 4.0 in pharmaceutical manufacturing [54].

10.0 Clinical and Therapeutic Applications

The clinical versatility of ODTs has led to their adoption across numerous therapeutic categories, offering enhanced compliance, reduced onset time, and improved bioavailability. ODT formulations are particularly beneficial for drugs requiring rapid action, low dosing, or improved palatability [55].

Centrally acting agents, such as olanzapine, risperidone, and selegiline, have been reformulated as ODTs for psychiatric and neurological indications. These formulations reduce the risk of non-adherence in patients with schizophrenia or Parkinson's disease by simplifying administration [56]. Antimigraine drugs, including zolmitriptan and rizatriptan, benefit from rapid dissolution, leading to faster relief compared with conventional tablets [57].

In pediatric populations, ODTs of montelukast, cetirizine, and paracetamol provide dosage convenience and eliminate the choking risk associated with traditional forms [58]. Likewise, in geriatric medicine, ODTs are increasingly preferred for cardiovascular and anti-hypertensive agents such as isosorbide dinitrate, amlodipine, and atenolol due to improved swallowability and onset [59].

The antiemetic category, particularly ondansetron and domperidone ODTs, has demonstrated substantial clinical success in chemotherapy-induced nausea and postoperative vomiting [60]. In pain management, tramadol and ibuprofen ODTs ensure rapid absorption through the buccal mucosa, offering efficient analgesic response.

Recent investigations have explored ODTs for biologics and peptides, leveraging nanocarrier systems and mucoadhesive polymers to overcome enzymatic degradation and enhance transmucosal absorption [61]. Thus, ODTs are no longer limited to conventional small molecules but are progressively adapting to complex therapeutics, marking a significant milestone in oral drug delivery evolution.

11.0 Regulatory and Quality Guidelines

The regulatory landscape for ODTs has evolved in parallel with their technological and clinical expansion. Regulatory bodies, including the United States Food and Drug Administration (FDA), the European Medicines Agency (EMA), and the World Health Organization (WHO), have issued clear guidance on ODT classification, testing, and labeling to ensure consistency and patient safety [62].

According to the FDA's Guidance for Industry, ODTs are defined as solid dosage forms containing medicinal substances that disintegrate rapidly typically within 30 seconds on the tongue. The disintegration test is performed without the use of mechanical agitation, simulating oral cavity conditions. The European Pharmacopoeia (Ph. Eur.) specifies a disintegration limit of 3 minutes but recommends optimization toward under 60 seconds for patient comfort [63].

Bioequivalence studies between ODTs and conventional tablets are required when the site of absorption or pharmacokinetic profile may differ. Regulatory authorities further mandate stability data in accordance with ICH Q1A(R2) and require compatibility testing for excipients, flavoring agents, and packaging components [64]. In addition to traditional regulatory frameworks, Quality-by-Design (QbD) and Process Analytical Technology (PAT) approaches are now widely applied in ODT manufacturing. These methodologies identify critical quality attributes (CQAs), critical material attributes (CMAs), and critical process parameters (CPPs) that influence disintegration and taste performance [65].

The emerging use of artificial intelligence (AI) and machine learning in regulatory science allows prediction of disintegration time, mechanical strength, and taste perception based on excipient properties and formulation parameters. Regulatory agencies are progressively recognizing these digital methodologies as supportive tools in formulation optimization and documentation [66].

13.0 CONCLUSION

Orally disintegrating tablets have matured from niche formulations to a globally recognized platform for rapid, patient-friendly drug delivery. Their success stems from an intricate interplay between formulation science, excipient engineering, and process innovation. Advances in lyophilization, direct compression, and emerging 3D printing methods have propelled ODTs into the forefront of modern pharmaceutics. Despite ongoing challenges particularly in taste masking, moisture stability, and high-dose drug incorporation recent technological and regulatory progress has addressed many historical limitations.

Future ODT development will likely integrate nanotechnology, computational modeling, and sustainable manufacturing, culminating in a new generation of smart, adaptive, and eco-friendly dosage forms. Ultimately, ODTs exemplify the pharmaceutical industry's shift toward patient-centric design, where therapeutic efficacy and user experience converge seamlessly. As personalized healthcare and precision dosing become mainstream, orally disintegrating tablets will remain an indispensable pillar in the evolution of global drug delivery systems.

REFERENCES

1. Fu Y, Yang S, Jeong SH, Kimura S, Park K. Orally fast disintegrating tablets: developments, technologies, taste-masking and clinical studies. *Crit Rev Ther Drug Carrier Syst.* 2004;21(6):433–76.
2. U.S. Food and Drug Administration. Guidance for Industry: Orally Disintegrating Tablets. Silver Spring, MD: U.S. FDA; 2008.
3. Seager H. Drug-delivery products and the Zydis fast-dissolving dosage form. *J Pharm Pharmacol.* 1998;50(4):375–82.
4. Hirani JJ, Rathod DA, Vadalia KR. Orally disintegrating tablets: a review. *Trop J Pharm Res.* 2009;8(2):161–72.
5. Abdelbary G, Elshafeey AH. Formulation of fast dissolving tablets using novel co-processed superdisintegrants. *Int J Pharm.* 2017;516(1–2):11–18.
6. Kuchekar BS, Badhan AC, Mahajan HS. Mouth dissolving tablets: a novel drug delivery system. *Pharma Times.* 2003;35(7):7–9.
7. Seager H. The Zydis fast-dissolving oral dosage form. *J Pharm Pharmacol.* 1998;50(4):375–82.
8. Brown D. Orally disintegrating tablets taste over speed. *Drug Del Technol.* 2003;3(6):58–61.
9. Saini S, Nanda A, Hooda M. Fast dissolving tablets: a review. *Int J Pharm Sci Rev Res.* 2016;38(1):13–21.

10. Nautiyal U, Gupta M, Sharma VK, et al. Fast dissolving tablets as a novel boon: a review. *J Pharm Chem Biol Sci.* 2014;2(1):5–26.
11. Aprecia Pharmaceuticals. *Spritam® (Levetiracetam) Prescribing Information.* U.S. FDA; 2015.
12. Khaled SA, Burley JC, Alexander MR, Roberts CJ. 3D printing of five-in-one dose combination polypills. *Int J Pharm.* 2015;494(2):643–650.
13. Patel DM, Shah RR, Prajapati BG. Design and evaluation of orodispersible tablets using superdisintegrant blends. *J Young Pharm.* 2020;12(1):47–52.
14. Mahapatra A, Nair V, Dubey R. Direct compression techniques for orally disintegrating tablets. *Int J Pharm Pharm Sci.* 2019;11(7):1–8.
15. Stange U, Führlein C, Eckert S, Rupprecht H. Sublingual and buccal administration of drugs. In: Niazi SK, ed. *Handbook of Pharmaceutical Manufacturing Formulations.* CRC Press; 2019.
16. Pandit V, Khanum A, Nair A. Ion-exchange resins in taste masking and controlled release formulations. *J Control Release.* 2020;322:240–258.
17. Dey P, Maiti S. Orodispersible tablets: a review. *Int J Pharm Bio Sci.* 2010;1(2):1–10.
18. Jadhav SA, Patil SV. Co-processed excipients in fast dissolving tablets: a review. *Int J Pharm Sci Res.* 2021;12(4):1920–30.
19. Patel JK, Vavia PR. Evaluation of co-processed excipients for direct compression of ODTs. *Drug Dev Ind Pharm.* 2015;41(8):1303–1312.
20. Khinchi MP, Gupta MK, Bhandari A, Sharma N. Superdisintegrants: an overview. *Asian J Pharm.* 2011;5(2):87–100.
21. Thakur R, Kashi H, Bhargava A. Comparative study of molding and sublimation methods in ODTs. *J Pharm Innov.* 2022;17(3):545–556.
22. Siddiqui N, Garg G, Sharma PK. Fast dissolving tablets: preparation, characterization and evaluation. *Int J Pharm Sci Rev Res.* 2011;9(1):87–96.
23. Patel BP, Patel JK, Rajput GC. A review on mouth dissolving tablet technology. *Int J Drug Deliv.* 2011;3(1):1–15.
24. Di Martino P, Censi R, Barthelemy A, Martino PD. Pharmaceutical applications of ODTs in CNS disorders. *Eur J Pharm Biopharm.* 2019;142:1–10.
25. Patil H, Tiwari RV, Repka MA. Pediatric formulations: ODTs and mini-tablets. *Adv Drug Deliv Rev.* 2019;151:139–155.
26. Pandey P, Gaur P, Singh M. ODTs for global health: improving access and adherence. *J Global Pharm Technol.* 2022;14(5):150–160.
27. European Pharmacopoeia Commission. *European Pharmacopoeia.* 11th ed. Strasbourg: Council of Europe; 2023.
28. United States Pharmacopeia (USP–NF 2024). *General Chapter <701> Disintegration.* Rockville, MD: USP; 2024.
29. Mirza S, Kumar P, Das M. Taste evaluation technologies for ODTs: a critical review. *Pharm Dev Technol.* 2018;23(6):525–538.
30. Gowthamarajan K, Kulkarni GT. NIR spectroscopy in pharmaceutical quality control. *J Pharm Anal.* 2021;11(5):451–463.
31. ICH Q1A(R2). *Stability Testing of New Drug Substances and Products.* Geneva: International Council for Harmonisation; 2023.
32. Sohi H, Sultana Y, Khar RK. Taste masking technologies in oral pharmaceuticals: recent developments and approaches. *Drug Dev Ind Pharm.* 2004;30(5):429–48.
33. EMA. *Guideline on the Pharmaceutical Development of Medicines for Oral Administration.* London: European Medicines Agency; 2020.
34. Singh A, Kaur G, Rana V. AI-assisted prediction of ODT disintegration. *Int J Pharm.* 2024;653:122–135.
35. Bansal AK, Saha S, Narang R. Sustainable excipient design for future oral dosage forms. *Green Chem Lett Rev.* 2023;16(2):200–215.
36. Huang J, Wang L, Zhao S, et al. Machine learning integrated electronic tongue for taste prediction in ODTs. *Int J Pharm.* 2023;648:122–131.
37. Fu Y, Park K. Fast-dissolving tablets based on phase transition of sugar alcohols. *J Control Release.* 2004;97(3):353–362.
38. Abdelbary G, Prinderre P, Eouani C, Joachim J, Reynier JP, Piccerelle PH. The preparation of orally disintegrating tablets using a hydrophilic waxy binder. *Int J Pharm.* 2004;278(2):423–433.
39. Mahapatra A, Dubey R, Nair V. Comparative study of fast disintegrating tablets of valsartan prepared by direct compression and lyophilization. *J Pharm Sci Tech.* 2021;14(3):201–215.
40. Bansal AK, Narang R. Sustainable pharmaceutical packaging innovations. *J Pharm Sustain Sci.* 2023;5(1):45–63.

41. Patel P, Wagh M, Kadam V. Formulation and development of orally disintegrating tablets: a future perspective. *Int J Pharm Sci Nanotech.* 2023;16(4):7000–7011.
42. Pandey V, Mishra S, Kumar N. Nanocrystal-loaded orally disintegrating tablets: enhanced bioavailability for poorly soluble drugs. *Eur J Pharm Sci.* 2022;178:106289.
43. Gupta S, Sharma A, Rathore R. 3D-printed ODTs: structure–property relationships and regulatory perspectives. *Addit Manuf.* 2023;71:103284.
44. Ahmed S, Khan H, Malik R. Sustainability in pharmaceutical manufacturing: green ODT technologies. *J Clean Prod.* 2024;412:137362.
45. Rajput R, Mehta S, Bhatt P. Hybrid film–tablet systems for pediatric oral drug delivery. *J Pharm Innov.* 2024;19(2):261–275.
46. Kaur G, Jain S, Singh A. Digital pharmaceutics and predictive modeling in ODT development. *Comput Biol Med.* 2024;169:107688.
47. Thakur R, Bhargava A, Kashi H. Comparative evaluation of co-processed superdisintegrants in ODT formulations. *J Pharm Innov.* 2022;17(3):545–556.
48. Deshmukh VN, Sakarkar DM. Formulation and evaluation of orodispersible tablets of cetirizine hydrochloride using superdisintegrants. *Int J Pharm Tech Res.* 2018;10(2):62–69.
49. Di Martino P, Censi R, Barthelemy A, Martino PD. Pharmaceutical applications of ODTs in CNS disorders. *Eur J Pharm Biopharm.* 2019;142:1–10.
50. Patil H, Repka MA. Pediatric formulations: ODTs and mini-tablets. *Adv Drug Deliv Rev.* 2019;151:139–155.
51. Pandey P, Gaur P, Singh M. ODTs for global health: improving access and adherence. *J Global Pharm Technol.* 2022;14(5):150–160.
52. Singh A, Kaur G, Rana V. AI-assisted prediction of ODT disintegration. *Int J Pharm.* 2024;653:122–135.
53. Khaled SA, Burley JC, Alexander MR, et al. 3D printing of five-in-one dose combination polypills. *Int J Pharm.* 2015;494(2):643–650.
54. Aprecia Pharmaceuticals. *Spritam® (Levetiracetam) Prescribing Information.* U.S. FDA; 2015.
55. Stange U, Führlein C, Eckert S, Rupprecht H. Sublingual and buccal administration of drugs. In: Niazi SK, ed. *Handbook of Pharmaceutical Manufacturing Formulations.* CRC Press; 2019.
56. European Pharmacopoeia Commission. *European Pharmacopoeia.* 11th ed. Strasbourg: Council of Europe; 2023.
57. Fu Y, Yang S, Jeong SH, Kimura S, Park K. Orally fast disintegrating tablets: developments, technologies, taste-masking and clinical studies. *Crit Rev Ther Drug Carrier Syst.* 2004;21(6):433–76.
58. Hirani JJ, Rathod DA, Vadalia KR. Orally disintegrating tablets: a review. *Trop J Pharm Res.* 2009;8(2):161–72.
59. Mahapatra A, Nair V, Dubey R. Direct compression techniques for orally disintegrating tablets. *Int J Pharm Pharm Sci.* 2019;11(7):1–8.
60. Jadhav SA, Patil SV. Co-processed excipients in fast dissolving tablets: a review. *Int J Pharm Sci Res.* 2021;12(4):1920–30.
61. Sohi H, Sultana Y, Khar RK. Taste masking technologies in oral pharmaceuticals. *Drug Dev Ind Pharm.* 2004;30(5):429–48.
62. EMA. *Guideline on the Pharmaceutical Development of Medicines for Oral Administration.* London: European Medicines Agency; 2020.
63. Singh A, Kaur G, Rana V. AI-assisted prediction of ODT disintegration. *Int J Pharm.* 2024;653:122–135.
64. Bansal AK, Saha S, Narang R. Sustainable excipient design for future oral dosage forms. *Green Chem Lett Rev.* 2023;16(2):200–215.
65. Huang J, Wang L, Zhao S, et al. Machine learning integrated electronic tongue for taste prediction in ODTs. *Int J Pharm.* 2023;648:122–131.
66. Ahmed S, Khan H, Malik R. Sustainability in pharmaceutical manufacturing: green ODT technologies. *J Clean Prod.* 2024;412:137362.